APIMEDS PHARMACEUTICALS US, INC.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2022 | — | $-713.6K | $6.2K |
| FY2023 | — | $31.9K | $410.5K |
| FY2024 | — | $-1.4M | $3.5K |
| FY2025 | — | $153.3M | $1.6M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2022 | — | $-713.6K | $6.2K |
| FY2023 | — | $31.9K | $410.5K |
| FY2024 | — | $-1.4M | $3.5K |
| FY2025 | — | $153.3M | $1.6M |